Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Real-world findings from the RESTORE registry presented at the 2025 MDA conference confirmed the established safety profile of onasemnogene abeparvovec over a 5-year period.

Long-Term Data Reinforces Safety of Gene Therapy Zolgensma for Spinal Muscular Atrophy

Patient advocate and MDA Ambassador Lily Sander shared inspiring perspective on Charcot-Marie-Tooth disease, advocacy efforts, and the importance of connection

NeuroVoices: Lily Sander on Advocacy, Community, and Raising Awareness for Charcot-Marie-Tooth Disease

Long-term follow-up data from an early-phase study of an AAV8-based gene therapy for DMD suggest the treatment was well-tolerated and provided sustained biochemical and functional benefits.

Early Trial Data Highlights Potential of Gene Therapy GNT0004 for Duchenne Muscular Dystrophy

Alpha Cognition has officially launched its new treatment for mild to moderate Alzheimer disease, with a focus on expanding patient access in the long-term care market.

AChEI Inhibitor Benzgalantamine (Zunveyl) Commercially Launched for Mild to Moderate Alzheimer Disease

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

The MyacarinG study post-hoc analysis demonstrated rozanolixizumab's potential to significantly reduce ocular symptoms in gMG, with consistent improvements across multiple scoring systems.

Ocular Symptoms of Myasthenia Gravis Improved With Rozanolixizumab

Videos

Kathleen Costello discusses her new role as interim CEO of the CMSC. She has the support of Jeff Wilken, CMSC president, and Tina Trott, CMSC director.

Continuing the Vision of June Halper: What's Next for CMSC

Interim chief executive officer of the Consortium of Multiple Sclerosis Centers.

The interim chief executive officer at the Consortium of Multiple Sclerosis Centers invites healthcare professionals to the Consortium’s annual meeting from May 28–31 in Phoenix, Arizona. [WATCH TIME: 2 minutes]

What to Expect From the 2025 CMSC Annual Meeting: Kathleen Costello, CRNP, MSCN

The child neurologist and neuroimmunologist at Nationwide Children’s Hospital delved into the unique challenges and research objectives surrounding MOG antibody-associated disease. [WATCH TIME: 3 minutes]

Challenges and Research Priorities for Pediatric MOGAD: Kelsey Poisson, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

ACTRIMS 2025

MDA 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Introduction to CMSC Best Practices in Multiple Sclerosis Therapies Roundtable 

Best Practices in Multiple Sclerosis

Best Practices in Multiple Sclerosis: Discussion

Best Practices for Therapeutic Selection in Relapsing Multiple Sclerosis

Therapeutic Selection in Relapsing Multiple Sclerosis: Key Concepts

Best Practices for Therapeutic Selection in Relapsing Multiple Sclerosis: Discussion

Therapeutic Selection for Progressive Multiple Sclerosis

Considerations in Therapeutic Selection for Progressive Multiple Sclerosis

Therapeutic Selection for Progressive Multiple Sclerosis: Discussion

Patients With Features of Aggressive Multiple Sclerosis or Poor Prognosis

Safety Concerns and Discussion: Highly Active Multiple Sclerosis

Therapeutic Goals of Treating Multiple Sclerosis 

Indicators of Suboptimal Therapies 

Therapeutic Selection in Pediatric-Onset Multiple Sclerosis

Best Practices for Treating Pediatric Patients

Therapeutic Selection in Pediatric-Onset Multiple Sclerosis: Discussion 

Best Practices for DMTs for Pregnant Patients With Multiple Sclerosis  

Multiple Sclerosis Drugs During Pregnancy 

Relapse Therapy and Postpartum Care for Pregnant Patients With Multiple Sclerosis 

Monitoring Efficacy of Treatment in Patients With Multiple Sclerosis 

Discussion: Monitoring Efficacy of Treatment in Patients With Multiple Sclerosis

Issues in Therapeutic Selection for Multiple Sclerosis 

Considerations When Selecting an Optimal DMT for Multiple Sclerosis Treatment 

Best Practices in Multiple Sclerosis Therapies: Future Perspectives

Expert Insights on the Best Practices of Multiple Sclerosis: Summary

Closing Thoughts: CMSC Best Practices in Multiple Sclerosis Therapies Roundtable

An expert-led panel discuss the best practices and different treatment considerations in multiple sclerosis.

Clinical

EMD-22-NRD0193 - /clinical/multiple-sclerosis

CMSC Best Practices in Multiple Sclerosis Therapies Roundtable